You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
基石藥業(02616.HK):舒格利單抗預計明年上半年獲EMA批准上市
阿思達克 08-16 10:25
基石藥業(02616.HK)首席執行官楊建新透露,舒格利單抗在英國和歐盟用於治療一線IV期NSCLC的兩項上市許可申請進展順利,近日已收到歐洲藥品管理局(EMA)的臨床試驗核查通知,預計將在2024年上半年獲批。 他表示,公司將積極尋求舒格利單抗與nofazinlimab(PD-1)在大中華區以外的開發與商業化合作夥伴,以推進藥物的海外商業化進程。 楊建新又指,未來公司將持續提升創新產品的研發能力,進一步拓展現有產品的商業潛力,並積極推進全球戰略佈局,為投資者、合作夥伴以及利益相關方創造更大的價值。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account